Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. The company is actively pursuing partnerships and has a promising pipeline, which is positive. However, there are uncertainties, such as lack of FDA engagement on ABS-201's Phase III design and undisclosed pricing strategies, which create concerns. The market opportunity is significant, but the absence of clear guidance tempers optimism.
Key Financial Performance
Revenue $700,000 in the fourth quarter, with no year-over-year change mentioned.
Research and Development Expenses $25.3 million for the three months ending December 31, 2025, compared to $18.4 million for the prior year period, representing an increase. The increase was primarily driven by advancement of Absci's internal programs, including direct costs associated with external preclinical and clinical development of ABS-101 and ABS-201.
Selling, General and Administrative Expenses $8.6 million for the three months ending December 31, 2025, compared to $8.8 million for the prior year period, representing a slight decrease.
Gain on Settlement of Contingent Consideration $5.1 million gain recorded during the fourth quarter of 2025, resulting in net proceeds of $8.7 million of unrestricted cash.
Cash, Cash Equivalents, and Marketable Securities $144.3 million as of December 31, 2025, compared to $152.5 million as of September 30, 2025, showing a decrease. The company believes this will fund operations into the first half of 2028.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ABS-201 Clinical Development: ABS-201 is in Phase I/IIa trials for androgenetic alopecia (AGA) and endometriosis. The drug has shown favorable safety data and is designed for infrequent dosing with potential for durable multiyear hair regrowth. Preliminary safety and PK data are expected in the first half of 2026, with proof-of-concept data in the second half.
Pipeline Expansion: Absci is advancing other programs (ABS-101, 301, and 501) and leveraging its AI platform for de novo antibody design. The company has reduced development timelines and costs significantly compared to industry standards.
Market Opportunity for ABS-201: The U.S. addressable market for ABS-201 in AGA is estimated at $25 billion annually, targeting 15-18 million consumers. The drug's anticipated profile includes durable hair regrowth and infrequent dosing, appealing to a premium market segment.
Endometriosis Market: Endometriosis affects 10% of women of reproductive age globally, with no FDA-approved disease-modifying therapies. ABS-201 targets a nonsex hormone pathway, offering potential differentiation and addressing significant unmet needs.
Operational Efficiency: Absci has advanced its first two programs from AI design to IND in approximately two years at $15 million per program, compared to the industry standard of 4-6 years and $50 million.
Financial Position: The company has $144.3 million in cash and equivalents as of December 31, 2025, sufficient to fund operations into the first half of 2028. Revenue for Q4 2025 was $700,000.
Strategic Focus: Absci is prioritizing ABS-201 development for AGA and endometriosis due to high ROI potential. The company is also exploring partnerships and early-stage asset transactions to generate non-dilutive cash inflows.
AI Platform Utilization: The Origin-1 AI platform has demonstrated capabilities in designing full-length antibodies against zero-prior epitopes, significantly enhancing Absci's drug development pipeline.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Risks: The development and clinical progress of ABS-201, including its potential expedited pathway from Phase I/IIa to Phase III, is subject to regulatory approval. Any delays or rejections from the FDA could significantly impact the company's timelines and market opportunities.
Clinical Trial Risks: The ongoing Phase I/IIa trial for ABS-201 involves safety, tolerability, and proof-of-concept data collection. Any adverse safety data or failure to meet efficacy endpoints could hinder further development and commercialization.
Market Adoption Risks: The commercial success of ABS-201 depends on its ability to meet the anticipated target product profile and gain acceptance among consumers and healthcare providers. Failure to achieve these could limit market penetration.
Competitive Landscape: The evolving competitive landscape, including other anti-prolactin receptor antibodies and alternative therapies, could impact the market opportunity and adoption of ABS-201.
Financial Risks: The company reported a decrease in cash reserves from $152.5 million to $144.3 million in Q4 2025. While current reserves are expected to fund operations until 2028, any delays or increased costs in clinical trials could strain financial resources.
Strategic Execution Risks: The company’s strategy to focus on ABS-201 and early-stage programs while seeking partnerships for other assets may face challenges if partnerships or collaborations do not materialize as planned.
Supply Chain and Operational Risks: The development of ABS-201 and other programs relies on efficient integration of AI design and wet lab validation. Any disruptions in these processes could delay timelines and increase costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ABS-201 Clinical Development: The company is advancing ABS-201 for androgenetic alopecia (AGA) and endometriosis. Preliminary safety, tolerability, and PK data for the ongoing Phase I/IIa trial will be shared in the first half of 2026. Interim 13-week proof-of-concept data, including exploratory efficacy endpoints, will be available in the second half of 2026, with full 26-week proof-of-concept data expected in early 2027. Phase II clinical trials for endometriosis are planned to begin in Q4 2026, supported by data from the Phase I/IIa trial.
Market Opportunity for ABS-201: The total addressable market for ABS-201 in the U.S. is estimated at $25 billion annually, targeting 15-18 million consumers with androgenetic alopecia. The product's anticipated profile includes a 2-3 year treatment durability with a premium pricing strategy. The company is exploring additional aesthetic outcomes, such as hair pigmentation restoration, which could expand the market further.
Regulatory and Development Pathway: The company is engaging with the FDA to explore an expedited clinical development strategy for ABS-201, potentially advancing directly from Phase I/IIa into Phase III registrational trials.
Financial Outlook: The company has $144.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025, sufficient to fund operations into the first half of 2028. Additional non-dilutive cash inflows may come from early-stage asset transactions or new platform collaborations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the target product profile (TPP) for ABS-201 in terms of efficacy?
A:The target product profile for ABS-201 aims to achieve durable treatment and efficacy at or above high-dose oral minoxidil, which is around 35 to 40 hairs per square centimeter. This would make it a highly attractive product. The product also emphasizes durability and convenient administration with just a few injections.
Q:What is the emerging safety profile of ABS-201?
A:The safety profile is favorable so far, with no evidence of on-target or off-target safety signals based on the data accumulated to date. The safety profile aligns with other studies and loss-of-function mutations in the prolactin receptor, which show no significant safety concerns.
Q:What is the expected duration of follow-up for a registrational study for ABS-201?
A:The company has not yet engaged with the FDA on the design of the Phase III program. However, they anticipate a 6-month primary endpoint with an additional 6 months of long-term safety data follow-up, based on predicates in the field.
Q:What is the status of drug creation partnerships with big pharma?
A:The company is actively negotiating and exploring deal structures for platform partnerships with big pharma. They are focused on doing the right deal rather than rushing into one. They also have a healthy pipeline of internal programs that they plan to initiate partnering discussions for later this year.
Q:Are ABS-301 and ABS-501 being considered for partnerships?
A:Yes, ABS-301 and ABS-501, which are in oncology, are better suited for partnerships as the company is focusing on I&I (inflammation and immunology) with ABS-201. They also have earlier-stage I&I pipeline programs that could be developed internally or partnered, depending on the cash balance sheet.
Q:What is the safety profile of ABS-201 in relation to nonhuman primates and other studies?
A:The safety profile is consistent with what has been observed in nonhuman primates and aligns with other studies targeting similar pathways. There are no mechanism-related safety signals or patterns of concern, although it is still early in the study.
Q:What data supports the ability of ABS-201 to engage the prolactin receptor in hair follicles?
A:Animal data, including studies with stem cell macaques and mice, suggest adequate tissue penetration of the antibody into hair follicles. The receptor occupancy was modeled using known biodistribution coefficients for the scalp and hair follicle.
Q:How does ABS-201 compare to other late-stage candidates like Fasoracetam and oral extended-release minoxidil?
A:ABS-201 is seen as synergistic with other treatments like oral minoxidil. It offers a novel mechanism targeting prolactin, which is upstream in driving hair loss. ABS-201 aims to provide durable hair regrowth with fewer doses, making it a premium product compared to daily oral minoxidil.
Q:What is the expected patient interest in ABS-201 compared to oral minoxidil?
A:Survey data shows high interest in ABS-201, with 92% of men and 89% of women currently using oral minoxidil expressing a strong inclination to seek out ABS-201. The product's durability, convenience, and fewer side effects make it highly attractive.
Q:How many patients have been dosed in the SAD portion of the ABS-201 trial?
A:Approximately 24 patients have been dosed in the SAD portion, based on the dosing of three cohorts.
Q:What are the challenges in developing a drug for endometriosis, particularly regarding pain measures?
A:Developing a drug for endometriosis involves challenges in selecting sites, patient selection, and mitigating placebo effects. Pain studies require careful protocol design and oversight to ensure accurate assessment of numerical rating scores.
Q:How is resource allocation being managed between AGA and endometriosis for ABS-201?
A:Both indications are considered significant opportunities. The company is leveraging the ongoing AGA trial to support initiating a Phase II trial in endometriosis, optimizing development efficiency. AGA trials recruit rapidly and require less investment compared to other indications.
Q:What is the market opportunity for ABS-201 in AGA and endometriosis?
A:Both indications represent large opportunities. AGA affects about 80 million Americans, while endometriosis affects 1 in 10 women worldwide. AGA is likely the larger opportunity, but both are significant.
Q:How will pricing differ between AGA and endometriosis markets for ABS-201?
A:Pricing details are not disclosed, but the company anticipates no significant arbitrage opportunity between the therapeutic payer market for endometriosis and the self-pay cosmetic market for AGA.
Q:What are the key differentiators of the company's AI-enabled discovery platform?
A:The platform's key differentiators include Origin-1 and zero-prior epitope design, which have been rigorously validated. The company is leveraging these models to develop pipeline assets and pursue platform partnerships.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the pricing strategy for ABS-201, stating that pricing would not be disclosed until the date of launch. Additionally, they did not provide a clear timeline or specifics on the FDA engagement for the Phase III program design, instead emphasizing the importance of the 13-week interim readout to guide future plans.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AGA endometriosis
Chief Medical
FDA
IIa headline
Medical Officer
Phase IIa
SAD
Somaratne Chief
Vertex
antibody
approval
consumer
estimate
hair
headline trial
mechanism
men woman
opportunity
pain
patient
platform
portion
product ABS
product profile
proof concept
research
safety tolerability
seminar
study
survey
therapy
tolerability PK
week proof
ABSI Transcript
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-10
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-5
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights promising developments, such as the potential $25 billion market for ABS-201, strong consumer interest, and strategic focus on I&I over oncology. The company's confidence in achieving receptor occupancy and the efficient use of agentic AI for cost reduction further strengthen the outlook. Despite some withheld details, the overall sentiment is positive, with expectations of significant growth and market impact.
Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call presents a mixed outlook. The company is actively pursuing partnerships and has a promising pipeline, which is positive. However, there are uncertainties, such as lack of FDA engagement on ABS-201's Phase III design and undisclosed pricing strategies, which create concerns. The market opportunity is significant, but the absence of clear guidance tempers optimism.
ABSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
